Drugs / MAGNE-B6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06386211 | Jul → Aug 2024 | — | Opella Healthcare Group SAS | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGNE-B6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06386211 ↗ |
| Route | Oral | “Oral solution.” NCT06386211 ↗ |